USA flag logo/image

An Official Website of the United States Government

SBIR Phase II: Megathura crenulata Post Larval Culture - Bottleneck for a…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
88247
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
0740238
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Stellar Biotechnologies, Inc.
332 E. Scott Street Port Hueneme, CA 93041
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: SBIR Phase II: Megathura crenulata Post Larval Culture - Bottleneck for a Valuable Medical Resource
Agency: NSF
Contract: 0848952
Award Amount: $461,566.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase II project will develop methods for the control of larval settlement, metamorphosis and postlarval growth of Megathura crenulata (keyhole limpet) to support the production of commercial quantities of Keyhole Limpet Hemocyanin (KLH), a unique and medically valuable marine natural product. Unlike many other prospective medical products from marine organisms, KLH is already in extensive use in over 20 KLH-based therapeutic vaccine trials. Phase I research successfully identified a critical ""cue"" for settlement of M. crenulata larvae and demonstrated the feasibility of achieving the long-term commercial objectives of this research. Phase II studies will translate the results from Phase I studies into prototype designs for testing and optimization of systems, diets and aquaculture methods for cultivation of the age-specific developmental phases, from metamorphosis to fully developed adults for KLH production. The broader impacts of this research are; 1) The elucidation of the underlying biochemical factors that promote settlement, metamorphosis and early postlarval survival of this carnivorous gastropod thus adding significantly to the body of scientific knowledge in this field and improving the potential for cultivation of other commercially important species with biomedical potential; 2) Providing sustainable commercial supplies of KLH for new, life-saving therapeutic vaccines for cancer, arthritis, hypertension, and other debilitating diseases, without continued dependence on the limited and threatened fishery, and; 3) Providing regulators and resource managers the opportunity to formulate management policies to protect the wild population without imposing limitations on KLH or the important KLH-based vaccines under development.

Principal Investigator:

Frank R. Oakes
BS
8054882147
foakes@stellarbiotech.com

Business Contact:

Frank R. Oakes
BS
8054882147
foakes@stellarbiotech.com
Small Business Information at Submission:

Stellar Biotechnologies, Inc.
417 E. Hueneme Rd. PMB #170 Port Hueneme, CA 93041

EIN/Tax ID: 770522411
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No